Tanios Bekaii-Saab, MD, FACP

Articles

Dr. Bekaii-Saab on the Uptake of Precision Medicine in CRC

June 17th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the uptake of precision medicine in colorectal cancer.

Dr. Bekaii-Saab on the Challenges of Utilizing Chemotherapy-Free Regimens in CRC

March 25th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the challenges of utilizing chemotherapy-free regimens in colorectal cancer.

Dr. Bekaii-Saab on the Toxicity Differences Between Regorafenib and TAS-102 in CRC

March 4th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer.

Dr. Bekaii-Saab Discusses Indicators of Progression in CRC

January 22nd 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses indicators of progression in colorectal cancer.

Dr. Bekaii-Saab on Incorporating Mechanisms of Resistance Into Treatment Selection in HCC

January 6th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses incorporating potential mechanisms of resistance into treatment selection in hepatocellular carcinoma.

Dr. Bekaii-Saab on Second-Line Treatment Options in HCC

July 8th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses second-line treatment options in hepatocellular carcinoma.

Tanios Bekaii-Saab, MD: Not Just Seeing the Light, But Getting Out of the Tunnel

November 27th 2019

Dr. Tanios Bekaii-Saab spent time discussing the path to practicing in gastrointestinal malignancies, how he navigates balancing his professional and personal life, and mottos he has lived by throughout his career and while caring for his patients.

Dr. Bekaii-Saab on POLO Trial Results in Pancreatic Cancer

July 17th 2019

Tanios Bekaii-Saab, MD, FACP, discusses the clinical implications of the results of the phase III POLO trial in metastatic pancreatic cancer.